Опыт применения анти-в-клеточной терапии ритуксимабом у детей с хронической воспалительной демиелинизирующей полирадикулоневропатией с описанием клинического случая

   Хроническая воспалительная демиелинизирующая полинейропатия (ХВДП), возникающая в детском возрасте, как правило, поддается лечению с применением стандартных иммуносупрессивных препаратов. Пациенты с рефрактерным течением могут иметь инвалидизирующие осложнения и нуждаются в генно­инженерной биологической те­рапии. В статье приводится информация о заболевании и описание случая ХВДП, реф­рактерного к стандартной терапии, с хорошим ответом на генно­инженерную биологи­ческую терапию ритуксимабом.

1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242–268. DOI: 10.1111/jns.12455.

2. Tsoumanis P, Kitsouli A, Stefanou C, et al. Chronic Inflammatory Demyelinating Polyneuropathy and Evaluation of the Visual Evoked Potentials : A Review of the Literature. Medicina (Kaunas). 2023 Dec 13;59(12):2160. DOI: 10.3390/medicina59122160.

3. Łukawska M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience. Front Neurol. 2021 Jul 2;12:667378. DOI: 10.3389/fneur.2021.667378. Erratum in: Front Neurol. 2022 Jan 21;12:784144.

4. Buch MH, Smolen JS, Betteridge N, et al. Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20. DOI: 10.1136/ard.2010.144998.

5. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68. DOI: 10.1038/sj.onc.1206939.

6. Fatehi F, Okhovat AA, Panahi A, et al. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst. 2021 Dec;26(4):469–474. DOI: 10.1111/jns.12461. Epub 2021 Sep 10.

7. Hu J, Sun C, Lu J, et al. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review and meta-analysis. J Neurol. 2022 Mar;269(3):1250–1263. DOI: 10.1007/s00415-021-10646-y. Epub 2021 Jun 12.

8. Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 May;61(5):575–579. DOI: 10.1002/mus.26804. Epub 2020 Jan 21.

9. Nepal G, Shing YK, Yadav JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis. Acta Neurol Scand. 2020 Nov;142(5):449–459. DOI: 10.1111/ane.13291. Epub 2020 Jun 16.

10. Yiu EM, Shield LK, Tewierik C, et al. Rituximab for treatment of refractory childhood chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol [Internet]. 2008 [cited 2024 Aug 28];119(3). Available from: https://findanexpert.unimelb.edu.au/scholarlywork/1641064-rituximab-for-treatment-of-refractory-childhood-chronic-inflammatory-demyelinating-polyneuropathy

11. D’Amico A, Catteruccia M, De Benedetti F, et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol. 2012 May;16(3):301–3. DOI: 10.1016/j.ejpn.2011.08.002. Epub 2011 Sep 7.

12. Ware TL, Kornberg AJ, Rodriguez-Casero MV, et al. Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. J Child Neurol. 2014 Jan;29(1):43–8. DOI: 10.1177/0883073812471719. Epub 2013 Jan 29.

13. Desai J, Ramos-Platt L, Mitchell WG. Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):327–30. DOI: 10.4103/0972-2327.160065.

14. Stevens JAE, Llewelyn G, Hartley L. Rituximab as an adjunct to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Paediatr Neurol. 2017 Jun;21:e114.

15. De Simoni D, Ricken G, Winklehner M, et al. Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. Neurology - Neuroimmunology Neuroinflammation. 2020;7(4): e763–. DOI:10.1212/NXI.0000000000000763.

16. Ko YJ, Shim YK, Kim WJ, et al. The Efficacy and Safety of Rituximab for the Treatment of Pediatric Autoimmune Neuroinflammatory Disorders at a Single Center. Ann Child Neurol. 2020;28(1):30–36.

17. Godil J, Barrett MJ, Ensrud E, et al. Refractory CIDP: Clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020 Nov 15;418:117098. DOI: 10.1016/j.jns.2020.117098. Epub 2020 Aug 15.

18. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142–50. DOI: 10.1212/WNL.0000000000000570. Epub 2014 Jun 11.

19. Nguyen AT, Cotteret C, Durrleman C, et al. Indications and Safety of Rituximab in Pediatric Neurology: A 10-Year Retrospective Study, Pediatric Neurology. 2022. Vol. 137. P. 41–48. ISSN 0887-8994. doi: 10.1016/j.pediatrneurol.2022.08.004

20. Ghezzi A, Banwell B, Bar-Or A, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal. 2021;27(12):1814–1822. DOI: 10.1177/1352458520932798.

21. Dou X, Li D, Wu Y, et al. Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis. Front Neurol. 2020 Dec 14;11:606923.